ERAS-4001 An oral pan-KRAS inhibitor in the BOREALIS-1 Phase 1 trial for patients with KRAS-mutant solid tumors.
Visit productCosigns Received
Be the first Cosign
Put your name behind ERAS-4001.
Add it to your Products I use list and share why you use it.